Abbisko Cayman (HKSE:02256) Other Financing: HK$-3.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02256 Abbisko Cayman Ltd HKSE:02256
56 GF Score
Price HK$10.54
GF Value HK$12.30
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Abbisko Cayman Other Financing?

Abbisko Cayman HKSE:02256 -2.95% 56 Other Financing is HK$-3.5 Mil as of Dec. 2025. GuruFocus rates HKSE:02256 with a GF Score™ of 56/100 and a GF Value™ of HK$12.30 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Abbisko Cayman's Other Financing for the six months ended in Dec. 2025 was HK$-2.6 Mil.

Abbisko Cayman's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-3.5 Mil.

Abbisko Cayman Other Financing Historical Data

* Premium members only.

The historical data trend for Abbisko Cayman's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman Other Financing Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -145.58 -13.25 -2.37 -1.72 -3.47

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.22 -0.96 -0.77 -0.82 -2.64
HKSE:02256
56GF Score
Abbisko Cayman Ltd HKSE:02256
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbisko Cayman Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-3.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-3.5 Mil mean?
Abbisko Cayman (HKSE:02256) has a Other Financing of HK$-3.5 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Abbisko Cayman and its competitors.
Is Abbisko Cayman's Other Financing too high?
Abbisko Cayman's current Other Financing is HK$-3.5 Mil. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Other Financing compare to VRTX and REGN?
Abbisko Cayman's Other Financing of HK$-3.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Abbisko Cayman and its competitors. Abbisko Cayman's current Other Financing is HK$-3.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Other Financing is HK$-3.5 Mil. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Other Financing is HK$-3.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?

Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued. The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30. GuruFocus considers Abbisko Cayman to be Modestly Undervalued.

Key valuation signals for HKSE:02256:

  • Other Financing: HK$-3.5 Mil
  • GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbisko Cayman Business Description

Other Exchanges 8ZD:Germany
Address Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score

Get the complete analysis for HKSE:02256

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$10.54
Price
HK$12.30
GF Value